• 1
    European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
  • 2
    Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, et al, for the Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283.
  • 3
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. HEPATOLOGY 2009; 50: 661-662.
  • 4
    Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, Liaw YF. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. HEPATOLOGY 2002; 35: 1522-1527.
  • 5
    Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. HEPATOLOGY 1991; 13: 627-631.
  • 6
    Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002; 123: 1084-1089.
  • 7
    Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow up. HEPATOLOGY 2007; 45: 1187-1192.
  • 8
    Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis: European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterol 1998; 93: 896-900.
    Direct Link:
  • 9
    Brunetto MR, Moriconi F, Bonino F, Lau GKK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. HEPATOLOGY 2009; 49: 1141-1145.
  • 10
    Lau GK, Marcellin P, Brunetto M, Button T, Batria R. On-treatment HBsAg decline during peginterferon alfa-2a(40KD) + lamivudine in patients with HBeAg-positive CHB as a potential predictor of durable off treatment response [Abstract]. HEPATOLOGY 2008; 48( Suppl. 1): 714A.
  • 11
    Moucari R, Mackiewicz V, Lada O, Riapult MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. HEPATOLOGY 2009; 49: 1151-1157.
  • 12
    Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50: 1084-1092.
  • 13
    Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. HEPATOLOGY 2006; 44: 675-684.
  • 14
    Chen J, Wang Z, Guo Y, Peng J, Sun J, Ahmed CS, et al. Serum HBsAg changes in HBeAg positive chronic hepatitis B patients with continuous viral load reductions during treatment with adefovir or peg-interferon-alpha-2a. Antiviral Res 2009; 81: 88-91.
  • 15
    Gane EJ, Heathcoate EJ, Marcellin P, Dusheiko G, Jacobson I, de Man R, et al. HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment [Abstract]. J Hepatol 2010; 52( Suppl 1.): S388.
  • 16
    Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
  • 17
    Liaw YF. HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B. Hepatol Int 2009; 3: 425-443.
  • 18
    Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al, for the GLOBE Study Group. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.
  • 19
    Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, Buti M, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51: 11-20.
  • 20
    Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia JD, Manns MO, et al. Efficacy and safety outcomes after 4 years of telbivudine treatment in patients with chronic hepatitis B (CHB) [Abstract]. HEPATOLOGY 2009; 50( Suppl. 1): 533A.
  • 21
    Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al, for the GLOBE Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588.
  • 22
    Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. HEPATOLOGY 2008; 48: 759-769.
  • 23
    Marcellin P, Avila C, Wursthorn K, Chuang W-L, Lau GK, Peng EJ, et al. Telbivudine (LdT) plus peg-interferon (PegIFN) in HBeAg-positive chronic hepatitis B (CHB)—very potent antiviral efficacy but risk of peripheral neuropathy (PN) [Abstract]. J Hepatol 2010; 52( Suppl. 1): S6-S7.
  • 24
    Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL, for the HBV 99-01 Study Group. Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101: 297-303.
    Direct Link:
  • 25
    Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010; 17: 16-22.
  • 26
    Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73-82.
  • 27
    Moucari R, Boyer N, Ripault MP, Castelnau C, Mackiewicz V, Dauvergne A, et al. Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients. J Viral Hepat 2010; doi:10.1111/j.1365-2893.2010.01332.x.
  • 28
    Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-522.
  • 29
    Nguyen T, Thompson A, Desmond P, Bowden S, Levy M, Locarnini S. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia J Hepatol 2010; 52: 508-513.
  • 30
    Sugiyama M, Tanaka Y, Kato T, Orito E, Ito K, Acharya SK, et al. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. HEPATOLOGY 2006; 44: 915-924.
  • 31
    Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg vs. anti-HBe positive carriers of hepatitis B virus. HEPATOLOGY 1983; 3: 656-662.
  • 32
    Naoumov NV, Portmann BC, Tedder RS, Ferns B, Eddleston AL, Alexander GJ, et al. Detection of hepatitis B virus antigens in liver tissue: a relation to viral replication and histology in chronic hepatitis B infection. Gastroenterology 1990; 99: 1248-1253.